Risankizumab
Risankizumab (pronounced as riz-an-kiz-u-mab) is a monoclonal antibody medication used for the treatment of moderate to severe plaque psoriasis. It is marketed under the brand name Skyrizi by AbbVie Inc..
Etymology
The name "Risankizumab" is derived from the International Nonproprietary Names (INN), where "zu" signifies humanized, "mab" stands for monoclonal antibody, and "risan" is a unique stem.
Pharmacology
Risankizumab works by binding to the p19 subunit of interleukin 23 (IL-23) and inhibiting its interaction with the cell surface receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. By inhibiting IL-23, Risankizumab helps to reduce the inflammation and other symptoms of psoriasis.
Related Terms
- Monoclonal Antibody - A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Psoriasis - A chronic skin condition that causes cells to build up rapidly on the surface of the skin.
- Cytokine - A type of protein that is important in cell signaling.
- Interleukin 23 - A cytokine that plays a key role in managing the immune system and inflammation.
Side Effects
Common side effects of Risankizumab include upper respiratory infections, headache, fatigue, injection site reactions, and fungal infections. Serious side effects may include serious infections, allergic reactions, and changes in liver function tests.
See Also
External links
- Medical encyclopedia article on Risankizumab
- Wikipedia's article - Risankizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski